SyntheMed and Pathfinder merge to create cell-based tech firm
This article was originally published in Clinica
Executive Summary
Biotechnology firm Pathfinder is set to merge with biomaterials specialist SyntheMed in a deal focused on the development of a new cell-based regenerative medicine for the treatment of various diseases.